Related Experiment Video
Updated: May 17, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Liver X receptor agonists decrease ENaC-mediated sodium transport in collecting duct cells
Abstract:
Liver X receptors (LXRs) are nuclear receptors that regulate cholesterol, fatty acid, and glucose metabolism in various tissues. However, the renal action of LXRs is not well understood. Here we investigated the effects of LXR-activating ligands on modulation of epithelial sodium channel (ENaC)-mediated sodium transport in collecting duct cells. Exposure of the M1 cells to the synthetic LXR agonists T0901317 and GW3965 or the natural ligand 22R-hydroxycholesterol for 24 h decreased amiloride-sensitive sodium transport, corresponding with an increase of transepithelial resistance. The inhibition of amiloride-sensitive sodium transport after incubation with T0901317 or GW3965 was not mediated by a reduction of Na(+)/K(+)-ATPase-mediated basolateral sodium transport. On the other hand, T0901317 and GW3965 decreased mRNA abundance and membrane expression of ENaC. Preincubation the monolayer with GW3965 attenuated aldosterone-induced stimulation sodium transport. In primary cultures of collecting duct cells, T0901317 and GW3965 similarly inhibited ENaC transport function as in M1 cells. This is the first evidence showing LXR-activating ligands modulate ENaC-mediated sodium transport in collecting duct cells. These results suggest that LXRs may represent a novel therapeutic target for treatment of conditions with dysregulation of ENaC such as hypertension.
Insights
Liver X receptors (LXRs) regulate metabolism. LXR ligands inhibit epithelial sodium channel (ENaC)-mediated sodium transport in kidney collecting duct cells, suggesting LXRs as a therapeutic target for hypertension.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Liver X receptors (LXRs) are key regulators of lipid, fatty acid, and glucose metabolism.
- The role of LXRs in renal function, particularly in regulating sodium transport, remains largely unexplored.
Discussion:
- LXR agonists T0901317, GW3965, and 22R-hydroxycholesterol reduced amiloride-sensitive sodium transport in M1 collecting duct cells.
- This inhibition was associated with increased transepithelial resistance and decreased ENaC mRNA and membrane expression, independent of Na+/K+-ATPase activity.
- LXR activation attenuated aldosterone-stimulated sodium transport and inhibited ENaC function in primary collecting duct cells.
Key Insights:
- LXR-activating ligands directly modulate ENaC-mediated sodium transport in kidney collecting duct cells.
- LXR ligands decrease ENaC abundance and function, impacting sodium reabsorption.
- These findings reveal a novel mechanism by which LXRs influence renal sodium handling.
Outlook:
- LXRs represent a potential therapeutic target for managing conditions characterized by ENaC dysregulation, such as hypertension.
- Further research into LXR-ENaC interactions could uncover new strategies for blood pressure control.
- Investigating the precise molecular pathways linking LXR activation to ENaC regulation is warranted.
Related Concept Videos
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion
Hepatic Drug Clearance: Role of Transporters

